Healthcare & life sciences sector

November 2023  |  SPECIAL REPORT: HEALTHCARE & LIFE SCIENCES

Financier Worldwide Magazine

November 2023 Issue

Q&A: Data analytics in life sciences

Using privacy by design techniques will allow life sciences firms to create and update their data protection posture in line with changing regulations. FW discusses data analytics in life sciences with Corey Dunbar and Jeff Lawton at BDO.

Strategic considerations in life sciences partnering

Davis Polk & Wardwell LLP Partnering transactions are never ‘one size fits all’. Instead, they are complex, bespoke arrangements that can take a variety of forms.

Cost-effective management of IP for life science companies

Stratagem IPM When cash is tight difficult decisions may need to be made in order to preserve existing intellectual property and cost effectively manage emerging IP.

Knee-jerk reaction to COVID-19 – lean times ahead for some

Burnet Duckworth & Palmer LLP Investors should be cautious of companies with a business plan centred on a pandemic response, especially since the largest portion of the value is derived from intellectual property.

Evaluating effort

Charles River Associates If contract terms used to describe the required level of effort are open to interpretation, identifying benchmarks may provide a reasonable first step in evaluating the licensee’s efforts.

EU regulation of artificial intelligence in healthcare

King & Spalding AI should be regulated taking into account the legal and regulatory principles and best practices already applicable to medicinal products and medical devices.

Q&A: Life sciences M&A

Current market conditions are fostering a more buyer-friendly environment than we have seen in recent years, which sellers should be prepared for. The transactional approach has changed as market players have become more risk averse. FW discusses life sciences M&A with Sonia de Kondserovsky, Andrew Gilbert, Qiang Li, Victoria Rhodes and Mathias Schulze Steinen at DLA Piper.

CONTRIBUTORS

BDO

Burnet Duckworth & Palmer LLP

Charles River Associates

Davis Polk & Wardwell LLP

DLA Piper

King & Spalding

Stratagem IPM

©2001-2024 Financier Worldwide Ltd. All rights reserved. Any statements expressed on this website are understood to be general opinions and should not be relied upon as legal, financial or any other form of professional advice. Opinions expressed do not necessarily represent the views of the authors’ current or previous employers, or clients. The publisher, authors and authors' firms are not responsible for any loss third parties may suffer in connection with information or materials presented on this website, or use of any such information or materials by any third parties.